Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449559 | 0.95 | CYP3A4 (0.35) | CYP3A4CYP2C19KAT8CYP19A1ALDH1A1 | |
| SCHEMBL24449426 | 0.89 | ALDH1A1 (0.40) | KAT8ALDH1A1EPHX2 | |
| SCHEMBL24448859 | 0.86 | ALDH1A1 (0.38) | CYP3A4CYP2C19KAT8ALDH1A1EPHX2 | |
| SCHEMBL4402799 | 0.84 | TSHR (0.39) | CYP3A4CYP2C19ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL4404400 | 0.84 | ALDH1A1 (0.43) | CYP3A4CYP2C19CYP19A1ALDH1A1ATM | |
| SCHEMBL24448812 | 0.83 | THRA (0.32) | ALDH1A1 | |
| SCHEMBL12945381 | 0.83 | CYP3A4 (0.35) | CYP3A4CYP2C19CYP19A1ALDH1A1ATM | |
| SCHEMBL13036988 | 0.82 | KAT8 (0.38) | CYP3A4CYP2C19KAT8CYP19A1ALDH1A1 | |
| SCHEMBL16994750 | 0.82 | KAT8 (0.38) | CYP3A4CYP2C19KAT8CYP19A1ALDH1A1 | |
| SCHEMBL24449464 | 0.80 | THRA (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | CYP3A4 4692/4885CYP2C19 4848/4885KAT8 6/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | CYP3A4 4692/4885CYP2C19 4848/4885KAT8 6/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | CYP3A4 820/4885CYP2C19 727/4885KAT8 4209/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | CYP3A4 4692/4885CYP2C19 4848/4885KAT8 6/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CYP3A4 639/4885CYP2C19 253/4885KAT8 2517/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CYP3A4 639/4885CYP2C19 253/4885KAT8 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.